Introduction to ARIA




WHAT IS ARIA?

Amyloid-related imaging abnormalities, also known as **"ARIA"**, are MRI abnormalities typically associated with the use of monoclonal antibodies that remove amyloid plaque in patients with Alzheimer's disease (AD)¹⁻³

ARIA is subdivided into **ARIA-E** (edema/effusion) or **ARIA-H** (hemosiderin/hemorrhage)^{2,3}

ARIA-E and -H may occur **concurrently**² as shown here: parenchymal edema + microhemorrhages⁵




MRI images data on file



ARIA MRI FINDINGS INCLUDE²⁻⁵:

- Parenchymal vasogenic edema (ARIA-E)
 Sulcal effusion (ARIA-E)
- Superficial siderosis (ARIA-H)
- Cerebral microhemorrhages (ARIA-H)
- Intracerebral hemorrhage (also termed macrohemorrhages)


ARIA-E (EDEMA/EFFUSION)



MRI images data on file

Parenchymal edema or sulcal hyperintense abnormalities detected on FLAIR sequences^{3,5}

ARIA-H (HEMOSIDERIN/HEMORRHAGE)




MRI images data on file

Microhemorrhages, superficial siderosis and/or rare lobar intracerebral hemorrhage observed as hypointense abnormalities detected on T2*GRE sequences^{3,5}

HYPOTHESIZED PATHOPHYSIOLOGY OF ARIA

ARIA is a consequence of the presence of amyloid in cerebral blood vessel walls (cerebral amyloid angiopathy [CAA]), which can cause **spontaneous ARIA**.⁴ The increased occurrence of ARIA-E seen with treatments that remove amyloid plaques is thought to be due to the removal and disruption of amyloid in blood vessel walls.⁴ Other mechanisms are also hypothesized⁶

Aggregation of toxic amyloid β (A β) species in the brain contributes to AD pathogenesis³ After the introduction of monoclonal antibodies that removes amyloid plaques, amyloid deposits begin to clear leading to increased vascular permeability⁶ This loss of vascular integrity may be thought of as a transient exacerbation of the effects of CAA^{5.} The leakage of fluid could give rise to an increased signal detected on FLAIR images (ARIA-E), while leakage of red cells would result in ARIA-H^{4,6} Limited evidence suggests that with repeated immunization and continued Aß clearance, the integrity of vessels and efficiency of clearance can improve and risk of ARIA decreases⁷




ARIA MAIN RISK FACTORS

APOE ε4 carrier status, treatment with monoclonal antibodies that remove amyloid plaque, and pretreatment history of microhemorrhages are risk factors for ARIA-E and ARIA-H^{4,5}



TREATMENT-RELATED ARIA OVERVIEW



REFERENCES:

- 1. Filippi M, et al. JAMA Neurol. 2022;79(3):291-304;
- 2. Barakos J, et al. AJNR Am J Neuroradiol. 2013;34(10):1958-1965;
- 3. Barakos J, et al. J Prev Alzheimers Dis. 2022;9(2):211-220;
- 4. Sperling RA, et al. Alzheimers Dement. 2011;7(4):367-385;
- 5. Cogswell PM, et al. AJNR Am J Neuroradiol. 2022;43(9):E19-E35;
- 6. Sperling RA, et al. Lancet Neurol. 2012;11:241-249;
- 7. Greenberg SM, et al. Nat Rev Neurol. 2020 Jan;16(1):30-42.
- 8. Salloway S, et al. JAMA Neurol. 2022;79(1):13-21;
- 9. VandeVrede L, et al. Alzheimers Dement (Amst). 2020 Oct 9;12(1):e121015;
- 10. Ostrowitzki S, et al. Alzheimers Res Ther 2017;9:95; 11. Ketter N, et al. J Alzheimers Dis 2017;57:557-573
- Ketter N, et al. J Alzheimers Dis 2017;57:557-573.
 Cummings J, et al. J Prev Alzheimers Dis. 2022;9(2):221-23
- 12. Cummings J, et al. J Prev Alzheimers Dis. 2022;9(2):221-230.

ABBREVIATIONS:

APOE ε4, ε4 allele of the Apolipoprotein E gene; Aβ, amyloid beta; AD, Alzheimer's disease; ARIA, amyloid-related imaging abnormalities (includes ARIA-E and H); ARIA-E, ARIA-edema/effusion; ARIA-H, ARIA-hemosiderin/hemorrhage; FLAIR, fluid-attenuated inversion recovery; GRE, gradient recalled-echo; MRI, magnetic resonance imaging; SWI, susceptibility weighted imaging.



For additional information

on ARIA, scan here:

www.UnderstandingARIA.com

